The estimated Net Worth of Stephen J Hoffman is at least $1.41 Миллион dollars as of 3 June 2021. Stephen Hoffman owns over 3,333 units of Dicerna Pharmaceuticals Inc stock worth over $1,111,094 and over the last 12 years he sold DRNA stock worth over $0. In addition, he makes $303,250 as Independent Director at Dicerna Pharmaceuticals Inc.
Sign up
Stephen Hoffman DRNA stock SEC Form 4 insiders trading
Stephen has made over 5 trades of the Dicerna Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 3,333 units of DRNA stock worth $127,387 on 3 June 2021.
The largest trade he's ever made was buying 700,000 units of Dicerna Pharmaceuticals Inc stock on 17 March 2015 worth over $5,775,000. On average, Stephen trades about 40,905 units every 92 days since 2012. As of 3 June 2021 he still owns at least 29,071 units of Dicerna Pharmaceuticals Inc stock.
You can see the complete history of Stephen Hoffman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Stephen Hoffman biography
Dr. Stephen J. Hoffman M.D. Ph.D. serves as Independent Director of the Company. Dr. Hoffman also currently serves on the Board of Directors of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Palleon Pharmaceuticals Inc., and Danforth Advisors. Dr. Hoffman served as Chief Executive Officer and director of Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO) from December 2017 until October 2019. Prior to that, he served as a senior advisor to PDL BioPharma, Inc. from February 2014 until November 2017. Previously he was a managing director at Skyline Ventures, a venture capital firm, from May 2007 until February 2014. From January 2003 to March 2007, Dr. Hoffman was a general partner at TVM Capital, a venture capital firm. From 1994 to 2002, he served as President, Chief Executive Officer and a member of the Board of Directors of Allos Therapeutics, Inc., a biopharmaceutical company, where he remained as Chairman of the Board of Directors until it was acquired by Spectrum Pharmaceuticals, Inc. in September 2012. From 1990 to 1994, Dr. Hoffman completed a fellowship in clinical oncology and a residency/fellowship in dermatology, both at the University of Colorado. Dr. Hoffman was the scientific founder of Somatogen Inc., a biotechnology company that was acquired by Baxter International, Inc. in 1998, where he held the position of Vice President of Science and Technology from 1987 until 1990. Previously, Dr. Hoffman also served on the Boards of Directors of Genocea Biosciences, Inc. (NASDAQ: GNCA), which he resigned from effective April 11, 2017, and Sirtris Pharmaceuticals, Inc., a pharmaceutical company that was acquired by GlaxoSmithKline (NYSE: GSK) in 2008. Dr. Hoffman holds a Ph.D. in bio-organic chemistry from Northwestern University and an M.D. from the University of Colorado School of Medicine.
What is the salary of Stephen Hoffman?
As the Independent Director of Dicerna Pharmaceuticals Inc, the total compensation of Stephen Hoffman at Dicerna Pharmaceuticals Inc is $303,250. There are 8 executives at Dicerna Pharmaceuticals Inc getting paid more, with Douglas Fambrough having the highest compensation of $5,048,130.
How old is Stephen Hoffman?
Stephen Hoffman is 66, he's been the Independent Director of Dicerna Pharmaceuticals Inc since 2007. There are 1 older and 12 younger executives at Dicerna Pharmaceuticals Inc. The oldest executive at Dicerna Pharmaceuticals Inc is Patrick Gray, 71, who is the Independent Director.
What's Stephen Hoffman's mailing address?
Stephen's mailing address filed with the SEC is C/O ACELRX PHARMACEUTICALS, INC., 1850 GATEWAY DRIVE, SUITE 175, SAN MATEO, CA, 94404.
Insiders trading at Dicerna Pharmaceuticals Inc
Over the last 11 years, insiders at Dicerna Pharmaceuticals Inc have traded over $233,644,011 worth of Dicerna Pharmaceuticals Inc stock and bought 2,456,100 units worth $36,501,331 . The most active insiders traders include Capital Management, Llc Kol..., Nicole Vitullo и Peter Kolchinsky. On average, Dicerna Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of $4,025,674. The most recent stock trade was executed by Douglas W. Pagan on 15 December 2021, trading 2,050 units of DRNA stock currently worth $78,351.
What does Dicerna Pharmaceuticals Inc do?
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using its proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna's GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, which expands on the functionality and application of its flagship liver-based GalXC technology, and has the potential to treat diseases across multiple therapeutic areas. In addition to its own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world's leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and its collaborative partners, they currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. Dicerna's mission is to interfere - to silence genes, to fight disease, to restore health.
What does Dicerna Pharmaceuticals Inc's logo look like?
Complete history of Stephen Hoffman stock trades at Acelrx Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Genocea Biosciences Inc и Aerpio Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc executives and stock owners
Dicerna Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Douglas Fambrough,
President, Chief Executive Officer, Director -
Robert Ciappenelli,
Chief Commercial Officer -
Bob Brown,
Executive Vice President, Research and Development, Chief Scientific Officer -
James Weissman,
Chief Operating Officer, Executive Vice President -
J. Kevin Buchi,
Independent Chairman of the Board -
Marc Kozin,
Independent Director -
Anna Protopapas,
Independent Director -
Adam Koppel,
Independent Director -
Stephen Hoffman,
Independent Director -
Martin Freed,
Independent Director -
Cynthia Smith,
Independent Director -
Patrick Gray,
Independent Director -
Ling Zeng,
Chief Legal Officer and Secretary -
Shreeram Aradhye,
Executive Vice President, Chief Medical Officer -
Douglas Pagan,
Chief Financial Officer -
Stephen Doberstein,
Independent Director -
Capital Management, Llc Kol...,
-
Partners Viii, L.P.Blair Ja...,
-
Theodore Ashburn,
See Remarks -
John B Green,
Chief Financial Officer -
David Madden,
Director -
Pankaj Bhargava,
Chief Medical Officer -
Viii Associates, L.P.Blair ...,
-
Bruce Peacock,
Director -
Ralf Rosskamp,
Chief Medical Officer -
Brian K Halak,
Director -
Regina M. Paglia,
Chief Human Resources Officer -
Capital Life Sciences Inves...,
-
Capital Management, Llcra C...,
-
Peter Kolchinsky,
Director -
Bart W Wise,
SVP, Legal Affairs -
Dennis Langer,
Director -
James C Blair,
10% owner -
Venture Partners V Lp Skyli...,
-
James E Dentzer,
Chief Financial Officer -
James E Deerfield Mgmt L.P....,
-
James E Deerfield Mgmt L.P....,
-
Vincent J Miles,
Director -
Capital Management Llcbrook...,
-
Kathleen K Schoemaker,
10% owner -
James E Deerfield Mgmt L.P....,
-
Nicole Vitullo,
10% owner -
Brian H Dovey,
10% owner -
Jesse I Treu,
10% owner -
Viii Associates, L.P. Dp,
10% owner -
Partners Viii, L.P. Domain,
10% owner